We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guideline Lays Out Parallel Review Timeline for Drug Development in EU
Guideline Lays Out Parallel Review Timeline for Drug Development in EU
Manufacturers looking to speed up drug approvals in the EU and ensure that their products are covered by payers should initiate parallel conversations with the European Medicines Agency and health technology assessment bodies early in the development process, the EMA says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor